

General Information

Name of the Company*	Saurat Pharmaceuticals Limited
NSE Symbol*	NOTLISTED
BSE Scrip Code*	530125
MSEI Symbol*	NOTLISTED
ISIN*	INE103E01016
Type of Announcement*	New
Type of Event*	Issue of duplicate share certificates/Letter of Confirmation
Details of other event	
Date of original announcement	
Remarks (website dissemination)	
Remarks for Exchange (not for Website Dissemination)	
Date of Report	14-05-2026

Issue of Duplicate Share Certificates/Letter of Confirmation

Number of shareholders to whom duplicate share certificate/Letter of Confirmation has been issued*											
Details of Shareholders to whom duplicate share certificate/Letter of Confirmation has been issued.											
Date of receipt of information for issue of duplicate share certificate/Letter of Confirmation*	Name*	Folio Number	Number of Shares	Old Certificate Number		New Certificate/Letter of Confirmation Number		Distinctive Number		Reason for issue of duplicate share certificate/Letter of Confirmation	Non-Compliance trigger
				From	To	From	To	From	To		
13-05-2026	Madhusudan Patra	13212	200	19203	19204	31009	31009	1920201	1920400		
Name of Registrar and Transfer Agent (RTA) of the Company*					Others						
Name of other RTA					MUG Intime India Private Limited						
Whether the Company has complied with Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*					Yes						
If No, specify the reason											
Any other disclosure w.r.t. compliance of any SEBI Act, Regulation, Circular or provision											
Any other information											
Remarks (website dissemination)											
Remarks for Exchange (not for Website dissemination)											



SAMRAT PHARMACHEM LIMITED
REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION
FROM : TN59 TO :- TN59

Tr.no /Appr.Dt	FOLIO NO. SHAREHOLDER'S NAME	CERT.NO		DIST.NOS		SHARES	PAID VALUE	STUS	Deno	Cert Type	MICR From	MICR To
		FROM	TO	FROM	TO							
TN59 13/05/2026	0013212 MADHUSUDAN PATRA	19203	19204	1920201	1920400	200 OLD ----- 200	10		200			
		31009	31009	1920201	1920400	200 NEW ----- 200	10	DUP	200			



SAMRAT PHARMACHEM LIMITED
REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION
FROM : TN59 TO :- TN59

***** BATCH CONTROLS*****

1. TOTAL NO.OF REQUESTS : 1
2. TOTAL NO.OF OLD CERTIFICATES : 2
3. TOTAL NO.OF NEW CERTIFICATES : 1
4. TOTAL NO.OF PAGES : 2

***** CERTIFICATE (S)CONTROLS *****

5. TOTAL NO.OF DUPLICATED CERTIFICATE : 1
6. TOTAL NO.OF DUPLICATED SHARES : 200
7. TOTAL NO.OF SUB DIVIDED CERTIFICATE : 0
8. TOTAL NO.OF SUB DIVIDED SHARES : 0
9. TOTAL NO.OF CONSOLIDATED CERTIFICATE 0
10. TOTAL NO.OF CONSOLIDATED SHARES 0

Samrat Pharmachem Limited

From: Alex Kundukulangara <alex.kundukulangara@in.mpms.mufg.com>
Sent: 12 May 2026 17:20
To: Samrat Pharmachem Limited
Cc: Raghunath Poojary
Subject: RE: Approval Date - Samrat Pharmachem Limited
Attachments: TN59 DUPLICATE REGISTER.pdf

Dear Ma'am,

Please find attached duplicate register as required.

Request you to kindly arrange for scanning and sharing signed copy of the same before couriering hard copy.

Thanks and Regards

Alex Kundukulangara
Associate – Client Relations



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services
(Formerly Link Intime India Private Limited)

C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083.

www.in.mpms.mufg.com | Follow us: [LinkedIn](#)

T: +91 22 4918 6000 M: +91 9619790927 (Ext: 2337)

alex.kundukulangara@in.mpms.mufg.com



Do you really need to print this email?

From: Samrat Pharmachem Limited <contact@samratpharmachem.in>
Sent: 11 May 2026 15:50
To: Alex Kundukulangara <alex.kundukulangara@in.mpms.mufg.com>
Cc: Raghunath Poojary <raghunath.poojary@in.mpms.mufg.com>; contact@samratpharmachem.in
Subject: RE: Approval Date - Samrat Pharmachem Limited

CAUTION : This email is received from an external domain. Open the hyperlink(s) & attachment(s) with caution.

Approval Date: 13-05-2026

Best Regards,

Sheetal
Samrat Pharmachem Limited

From: Alex Kundukulangara [<mailto:alex.kundukulangara@in.mpms.mufg.com>]
Sent: 11 May 2026 12:10
To: SAMRAT PHARMACHEM LIMITED <contact@samratpharmachem.in>
Cc: Raghunath Poojary <raghunath.poojary@in.mpms.mufg.com>
Subject: Approval Date - Samrat Pharmachem Limited

Dear Sir/Ma'am,

We have received duplicate request(s) for 1 shareholder.

Inward Certificate No.	Inward Certificate Date	Seller Folio	Seller Name	Buyer Folio No	Buyer Name
DU1326	20/04/2026	0013212	MADHUSUDAN PATRA	0013212	

Kindly provide approval date for our further course of action.

Thanks and Regards

Alex Kundukulangara
Associate – Client Relations



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services
(Formerly Link Intime India Private Limited)

C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083.
www.in.mpms.mufg.com | Follow us: [LinkedIn](#)

T: +91 22 4918 6000 M: +91 9619790927 (Ext: 2337)
alex.kundukulangara@in.mpms.mufg.com



Do you really need to print this email?

DISCLAIMER: This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does

not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.

DISCLAIMER: This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3444-3445, GIDC,
Phase 4, Ankleshwar – 393002,
Gujarat, India
Tel : +91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400058, India.
Tel : +91-7507534567 / 8760345678
Email: contact@samratpharmachem.in

TO WHOM SO EVER IT MAY CONCERN

Transmitting Animal Spongiform Encephalopathy (TSE) / Bovine Spongiform Encephalopathy (BSE) Declaration

We declare and certify that the product: **Hydriodic Acid**
manufactured at our following site:

Plot No. A2/3444-3445, GIDC, Phase 4, Ankleshwar - 393002, Gujarat.

contains no ingredients of animal origin and no materials derived from or exposed to animals affected by or under quarantine for Transmitting Animal Spongiform Encephalopathy (TSE) / Bovine Spongiform Encephalopathy (BSE).

The product is produced in the facility where no animal, animal products, animal by-products, veterinary vaccines or animal pathogens are maintained and are packed in a packing that can be identified as to the nature of the products and the country of origin.

For Samrat Pharmachem Limited

Mr. Lalit Mehta

Managing Director

15/05/2026